Monitoring of Immunological Mechanisms and Biomarkers Underlying Efficacy and Toxicity of Cancer Immunotherapy

NARecruitingINTERVENTIONAL
Enrollment

570

Participants

Timeline

Start Date

May 28, 2018

Primary Completion Date

November 30, 2029

Study Completion Date

November 30, 2029

Conditions
Solid Cancers
Interventions
OTHER

Patients treated with immune checkpoint blockade

"Tumor biopsy specimens and blood samples will be collected at different time points:~* Baseline~* before the 3rd ICB administration (blood samples only)~* before the 5th ICB administration (blood samples only)~* at the time of treatment permanent discontinuation (blood samples only)~* at the time of progression (tumor biopsy specimens only)~* after the last dose of ICB treatment (blood samples only taken twice per year until study termination)"

Trial Locations (3)

31059

RECRUITING

Hopital Larrey, Toulouse

RECRUITING

Institut Universitaire Du Cancer de Toulouse - Oncopole, Toulouse

Unknown

RECRUITING

Chu Rangueil, Toulouse

All Listed Sponsors
lead

Institut Claudius Regaud

OTHER